Analysing saturable antibody binding based on serum data and pharmacokinetic modelling

Physics in Medicine and Biology

Volumn 56, Issue 1, 2011, Pages 73-86

  Kletting, Peter ^a   Kiryakos, Hady ^a   Reske, Sven N ^a   Glatting, Gerhard ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY MEASUREMENTS; ACUTE LEUKAEMIA; AKAIKE INFORMATION CRITERION; ANTIBODY BINDING; ANTIBODY BINDING SITES; BIODISTRIBUTIONS; DOSE CALCULATION; GENERAL METHOD; IMMUNOREACTIVITIES; MODEL PARAMETERS; NON-LINEAR MODEL; PHARMACOKINETIC MODEL; RADIOIMMUNOTHERAPY;

ANTIBODIES; BIOCHEMISTRY; BODY FLUIDS; PHARMACOKINETICS; RADIOTHERAPY;

BINDING SITES;

CD66 ANTIGENS; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BINDING SITE; BIOLOGICAL MODEL; BLOOD; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BINDING SITES; CELL ADHESION MOLECULES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MODELS, BIOLOGICAL; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

EID: 79551668669     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/56/1/005     Document Type: Article

References (25)

1. Barrett P H, Bell B M, Cobelli C, Golde H, Schumitzky A, Vicini P and Foster D M 1998 SAAM II: simulation, analysis, and modelling software for tracer and pharmacokinetic studies Metabolism 47 484-92
2. Buchmann I, Meyer R G, Mier W and Haberkorn U 2009 Myeloablative radioimmunotherapy in conditioning prior to haematological stem cell transplantation: closing the gap between benefit and toxicity? Eur. J. Nucl. Med. Mol. Imaging 36 484-98
3. Burnham K P and Anderson D R 2002 Model Selection and Multimodel Interference - A Practical Information-Theoretic Approach (New York: Springer)
4. Carrasquillo J A et al 1999 Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution J. Nucl. Med. 40 268-76
5. Dower S K and Segal D M 1985 Interaction of monoclonal antibodies with MHC class I antigens on mouse spleen cells. II. Levels of expression of H-2K, H-2D, and H-2L in different mouse strains J. Immunol. 134 431-5
6. Eger R R, Covell D G, Carrasquillo J A, Abrams P G, Foon K A, Reynolds J C, Schroff R W, Morgan A C, Larson S M and Weinstein J N 1987 Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans Cancer Res. 47 3328-36
7. Ferl G Z, Wu A M and DiStefano J J III 2005 A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn) Ann. Biomed. Eng. 33 1640-52
8. 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study Eur. J. Nucl. Med. Mol. Imaging 36 1443-52
9. Glatting G, Kletting P, Reske S N, Hohl K and Ring C 2007 Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test Med. Phys. 34 4285-92
10. Glatting G, LandmannM, Kull T,Wunderlich A, Blumstein NM, Buck A K and Reske S N 2005 Internal radionuclide therapy: the UlmDos software for treatment planning Med. Phys. 32 2399-405
11. Glatting G et al 2006 Anti-CD45 monoclonal antibody YAML568: a promising radioimmunoconjugate for targeted therapy of acute leukemia J. Nucl. Med. 47 1335-41
12. Green A J, Johnson C J, Adamson K L and Begent R H 2001 Mathematical model of antibody targeting: important parameters defined using clinical data Phys. Med. Biol. 46 1679-93
13. Illidge T M et al 2009 Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy Blood 113 1412-21
14. Kaufman E N and Jain R K 1992 Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays Cancer Res. 52 4157-67
15. Kletting P, Bunjes D, Reske S N and Glatting G 2009a Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model J. Nucl. Med. 50 296-302
16. Kletting P and Glatting G 2009 Model selection and inference in pharmacokinetics: the corrected Akaike information criterion and the F-test Z. Med. Phys. 19 200-6
17. Kletting P, Kull T, Bunjes D, Mahren B, Luster M, Reske S N and Glatting G 2010 Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model J. Nucl. Med. 51 484-91
18. Kletting P, Kull T, Reske S N and Glatting G 2009b Comparing time activity curves using the Akaike information criterion Phys. Med. Biol. 54 N501-7
19. Mazerolle M J 2004 Mouvements et reproduction des amphibiens en tourbières perturbées Thesis Université Laval, Canada
20. Ringhoffer M et al 2005 188Re- or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study Br. J. Haematol. 130 604-13
21. Sharkey R M and Goldenberg D M 2008 Use of antibodies and immunoconjugates for the therapy of more accessible cancers Adv. Drug Deliv. Rev. 60 1407-20
22. Silbernagl S and Despopoulos A 2003 Taschenatlas der Physiologie (Stuttgart: Thieme)
23. Stabin M G and Brill A B 2008 State of the art in nuclear medicine dose assessment Semin. Nucl. Med. 38 308-20
24. Vicini P, Brill A B, Stabin M G and Rescigno A 2008 Kinetic modeling in support of radionuclide dose assessment Semin. Nucl. Med. 38 335-46
25. Yates J W, Jones R D, Walker M and Cheung S Y 2009 Structural identifiability and indistinguishability of compartmental models Expert Opin. Drug Metab. Toxicol. 5 295-302